General Biologicals Corporation
4117
Rank in Stocks
#27058
General Biologicals Corporation (GBC) is a company dedicated to the research,... General Biologicals Corporation (GBC) is a company dedicated to the research, development, production, and global commercialization of in-vitro diagnostic (IVD) solutions, operating extensively both within Taiwan and internationally. The company's core diagnostic offerings include advanced ELISA and chemiluminescence immunoassays, molecular and cellular diagnostic platforms, and rapid point-of-care testing (POCT) systems. Its diverse portfolio further encompasses COVID-19 related solutions, digital pathology, and contract development manufacturing organization (CDMO) services. Additionally, GBC provides essential blood screening services for detecting hepatitis and HIV, alongside crucial biomaterials such as antibody preparations and human plasma. Venturing beyond diagnostics, the company also markets a line of oral care products under its proprietary 'oh care' brand. These diagnostic systems are primarily utilized by clinics and laboratories. Founded in 1973, General Biologicals Corporation is headquartered in Hsinchu City, Taiwan.
Share Price
$0.24082722
Last synced: 2026-11-10
Market Cap
$16.94M
Change (1 day)
-3.07%
Change (1 year)
-39.56%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade General Biologicals Corporation (4117)
Category
Healthcare
EPS for General Biologicals Corporation (4117)
EPS as of June 2026 TTM: $0.27
According to General Biologicals Corporation's latest financial reports, its current EPS (TTM) is $0.27. At the end of 2025 the company had an EPS of $0.25, an increase over its 2024 EPS of $-0.11.
EPS history for General Biologicals Corporation from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.27 | 9.52% |
| 2025 | $0.25 | -320.82% |
| 2024 | $-0.11 | 3.88% |
| 2023 | $-0.11 | 273.10% |
| 2022 | $-0.03 | -208.61% |
| 2021 | $0.03 | -36.43% |
| 2020 | $0.04 | -226.89% |
| 2019 | $-0.03 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $8.45 | 2,986.19% |
IE
|
|
| $0.21 | -23.85% |
CN
|
|
| $19.69 | 7,090.94% |
CH
|
|
| $4.34 | 1,484.37% |
CH
|
|
| $0.13 | -53.98% |
CN
|
Questions about General Biologicals Corporation's earnings per share (EPS)
What is General Biologicals Corporation's earnings per share (EPS)?
General Biologicals Corporation's earnings per share (EPS) over the last twelve months is $0.27, as of Jun 2026.
What was General Biologicals Corporation's earnings per share (EPS) in 2025?
In 2025, General Biologicals Corporation's earnings per share (EPS) was $0.25, compared with $-0.11 in 2024.
How has General Biologicals Corporation's earnings per share (EPS) changed since 2020?
From 2020 to 2025, General Biologicals Corporation's earnings per share (EPS) went from $0.04 to $0.25, an average growth of 44.27% a year.
How does General Biologicals Corporation's earnings per share (EPS) compare with similar companies?
General Biologicals Corporation's earnings per share (EPS) ($0.27) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Ypsomed Holding AG, with $19.69.